PEAK6 Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

PEAK6 Group’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$503K	Hold	6,000	–	–	﹤0.01%	2589
2018 Q1	$369K	Sell	6,000 -15,300	-72%	-$922K	﹤0.01%	2863
2017 Q4	$1.24M	Sell	21,300 -4,900	-19%	-$309K	0.01%	1753
2017 Q3	$1.52M	Buy	26,200 +3,000	+13%	+$323K	0.01%	1608
2017 Q2	$2.81M	Buy	23,200 +3,000	+15%	+$348K	0.02%	1076
2017 Q1	$2.29M	Sell	20,200 -4,100	-17%	-$479K	0.02%	1042
2016 Q4	$2.64M	Buy	24,300 +12,600	+108%	+$1.5M	0.02%	1102
2016 Q3	$1.93M	Buy	11,700 +10,600	+964%	+$1.67M	0.01%	1307
2016 Q2	$157K	Buy	+1,100	New	+$160K	﹤0.01%	3304
2016 Q1	–	Sell	-7,400	Closed	-$1.1M	–	5191
2015 Q4	$1.1M	Buy	7,400 +500	+7%	+$84.6K	0.01%	1838
2015 Q3	$1.14M	Buy	6,900 +4,900	+245%	+$1.08M	0.01%	2066
2015 Q2	$483K	Buy	2,000 +1,500	+300%	+$399K	﹤0.01%	2796
2015 Q1	$141K	Buy	+500	New	+$108K	﹤0.01%	3724
2014 Q3	–	Sell	-4,500	Closed	-$1.06M	–	5305
2014 Q2	$1.06M	Buy	4,500 +3,900	+650%	+$1.03M	0.01%	1588
2014 Q1	$198K	Buy	+600	New	+$202K	﹤0.01%	3440

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PEAK6 Group's ICPT Position: Q2 2018 in Review

PEAK6 Group reduced its Intercept Pharmaceuticals, Inc. (ICPT) stake by 57% in Q2 2018, selling an estimated $61.4K and leaving 624 shares worth $52K. The position accounts for ﹤0.01% of the portfolio, ranked #3916.

PEAK6 Group first reported a position in ICPT in Q1 2014 and has held it in 13 quarters since. The position peaked at $1.1M in Q3 2017. 163 funds tracked by Wall St. Rank hold ICPT as of Q2 2018.

PEAK6 Group held 624 shares of Intercept Pharmaceuticals, Inc. worth $52K as of Q2 2018.
PEAK6 Group sold 838 Intercept Pharmaceuticals, Inc. shares in Q2 2018, an estimated $61.4K.
Intercept Pharmaceuticals, Inc. made up ﹤0.01% of PEAK6 Group's portfolio in Q2 2018, its #3916 holding.
PEAK6 Group first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2014 and has held it in 13 quarters since.
PEAK6 Group's Intercept Pharmaceuticals, Inc. position peaked at $1.1M in Q3 2017.
163 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.